Homocysteine, cystatin C and N-terminal-pro brain natriuretic peptide: Vascular risk markers in elderly patients with mental illness

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 1, 2007, Pages 88-96

  Nilsson, Karin ^a   Gustafson, Lars ^a   Hultberg, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cystatin C; Homocysteine; N terminal pro brain natriuretic peptide; Psychogeriatric patients; Vascular disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; COBALAMIN; CREATININE; CYSTATIN C; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; INTRACRANIAL PRESSURE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NEUROIMAGING; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SERUM; VASCULAR DISEASE; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BRAIN; CYSTATIN C; CYSTATINS; DEMENTIA; DEPRESSION; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 37349128314     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111994     Document Type: Article

References (53)

1. Nilsson K, Gustafson L, Fäldt R, Andersson A, Brattström L, Lindgren A, Israelsson B, Hultberg B: Hyperhomocysteinemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-859.
2. Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, Dejaeger E: Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Med Sci 1997;52:M76-M79.
3. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
4. McCaddon A, Davies G, Hudson P, Tandy S, Cattel H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
5. Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia 1999;10:12-20.
6. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype and risk for stroke, vascular dementia and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-2356.
7. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U: Homocysteine, folate and vitamin B-12 in mild cognitive impairment, Alzheimer's disease and vascular dementia. Am J Clin Nutr 2004; 80:114-122.
8. Pollak DR, Pollak A, Idelson M, Bejarano-Achache I, Doron D, Blumenfeld A: The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia. J Am Geriatr Soc 2000;48:664-668.
9. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ: Homocysteine vitamin B-6 and vascular disease in AD patients. Neurology 2002;58:1471-1475.
10. Ravaglia G, Forti P, Maioli F, Muscari A, Sacchetti L, Arnone G, Nativio V, Talerico T, Mariani E: Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr 2003;77:668-673.
11. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary I: Homocysteine, B-vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-913.
12. Morris MS, Jacques PF, Rosenberg IH, Selhub J: Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001;73:927-933.
13. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL: Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan study. Neurology 2004;63:254-260.
14. Garcia A, Zanibbi K: Homocysteine and cognitive function in elderly people. CMAJ 2004;171:897-904.
15. Ellison M, Thomas J, Patterson A: A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 2004;17:371-383.
16. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, Schneede J, Blom HJ, Hoefnagels WH, van Staveren WA: Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006;84:361-370.
17. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-1209.
18. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
19. Refsum H, Smith DA, Ueland PM, Nexö E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
20. Nilsson K, Gustafson L, Hultberg B: Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:7-12.
21. Nilsson K, Gustafson L, Hultberg B: Plasma homocysteine concentration and its relation to symptoms of vascular disease in psychogeriatric patients. Dement Geriatr Cogn Disord 2005;20:35-41.
22. Nilsson K, Gustafson L, Hultberg B: Plasma homocysteine and vascular disease in elderly patients with psychogeriatric disease. Dement Geriatr Cogn Disord 2006;21:148-154.
23. Nilsson K, Gustafson L, Hultberg B: Plasma homocysteine, cobalamin/folate status, and vascular disease in a large population of psychogeriatric patients. Dement Geriatr Cogn Disord 2006;22:358-366.
24. Nilsson K, Gustafson L, Hultberg B: Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis. Dement Geriatr Cogn Disord 2007;24:162-168.
25. Mielke MM, Zandi PP: Hematologic risk factors of vascular disease and their relation to dementia. Dement Geriatr Cogn Disord 2006;21:335-352.
26. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
27. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49-55.
28. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, van Broeckhoven C, Grobbee DE: Atherosclerosis apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.
29. Ott A, Breteler MM, de Bruyne MC, van Harskamp FC, Grobbee DE, Hofman A: Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321.
30. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K: Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161-1168.
31. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-1942.
32. Gustafson D, Rotenberg E, Blennow K, Steen B, Skoog I: An 18-year follow-up of overweight and risk of Alzheimer's disease. Arch Intern Med 2003;163:1524-1528.
33. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R: Stroke and the risk of Alzheimer's disease. Arch Neurol 2003;60:1707-1712.
34. Kalaria R: Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002;203:29-34.
35. Korczyn AD: The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005;229-230:3-6.
36. Alagiakrishnan A, McCracen P, Feldman H: Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J 2006;82:101-105.
37. Struthers AD, Davies J: B-type natriuretic peptide: a simple new test to identify coronary artery disease? QJM 2005;98:765-769.
38. Bökenkamp A, Herget-Rosenthal S, Bökenkamp R: Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006;21:1223-1230.
39. American Psychiatric Association: DSM IV. Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
40. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International workshop. Neurology 1993;43:250-260.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan M: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
42. Nilsson K, Gustafson L, Fäldt R, Andersson A, Hultberg B: Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994;24:600-606.
43. Nilsson K, Gustafson L, Fäldt R, Andersson A, Vaara I, Nilsson R, Alm B, Hultberg B: Plasma methylmalonic acid in relation to serum cobalamin and plasma homocysteine in a psychogeriatric population and the effect of cobalamin treatment. Int J Geriatr Psychiatry 1997;12:62-72.
44. Andersson A, Isaksson A, Brattström L, Hultberg B: Homocysteine and other thiols determined in plasma by HPLC and thiolspecific post-column derivatization. Clin Chem 1993;39:1590-1597.
45. Galasko GIW, Lahiri A, Barnes SC, Collison P, Senior R: What is the normal range for Nterminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-2276.
46. Toole JF, Malinow MR, Chambless LE, et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
47. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT trial investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
48. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
49. Loscalzo J: Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-1632.
50. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129.
51. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullogh PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 2003;108:2154-2169.
52. Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenk H, Hultberg B: The increase of plasma homocysteine concentration with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998;36:175-178.
53. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O: Plasma N-terminal pro-BNP as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48:156-163.